Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31425815 | 1.00 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL25224056 | 0.81 | MAPK1 (0.50) | ALDH1A1MAPTKMT2APOLBCXCR1 | |
| SCHEMBL21646246 | 0.80 | CXCR1 (0.40) | ALDH1A1RAB9AMAPTKMT2APOLB | |
| SCHEMBL28198924 | 0.80 | HTT (0.63) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL22941509 | 0.78 | CXCR1 (0.48) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL30899389 | 0.78 | CXCR1 (0.48) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL23167730 | 0.76 | CXCR1 (0.42) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL23833622 | 0.75 | CYP3A4 (0.51) | ALDH1A1MAPTKMT2APOLBHTT | |
| SCHEMBL30096933 | 0.75 | CYP3A4 (0.51) | ALDH1A1MAPTKMT2APOLBHTT | |
| SCHEMBL19983126 | 0.75 | SMN1; SMN2 (0.51) | ALDH1A1NPC1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | SYNTARA LIMITED (AU) | 2024-12-31 | — | — | US | disclosed |
| EP-3829520-B1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LTD (AU) | 2024-11-27 | — | — | EP | disclosed |
| CN-112533897-B | Halogenated allylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
| EP-3829520-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | Pharmaxis Ltd. (AU) | 2021-06-09 | — | — | EP | disclosed |
| CN-112533897-A | Haloallylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2020024017-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020024017-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | LOX, DAO, LOXL1 | ALDH1A1 303/4885NPC1 3171/4885RAB9A 2349/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | ALDH1A1 1582/4885NPC1 682/4885RAB9A 3931/4885 |
| US-20210353571-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, LOXL1 | ALDH1A1 303/4885NPC1 3171/4885RAB9A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.